Department: Comparative Biomedical Sciences

Campus: Camden

Research Groups: Cardiovascular and Inflammation Biology and Metabolism, Immune Regulation and Cancer

David is a Senior Lecturer in the Department of Comparative Biomedical Sciences. His research focuses on vascular and inflammation resarch, with a particular interst in the roles of lipids and lipid dervied mediators.

Dr Bishop-Bailey initially studied for a degree in Pharmacology at Kings College London. During this BSc he had the opportunity to work for a year in the lab of the Nobel Laureate Sir John Vane at the William Harvey Research Institute (WHRI), London, UK with Prof Chis Thiemermann and Prof Jane Mitchell. After the award of his BSc, he then was awarded a British Heart Foundation PhD studentship at the National Heart and Lung Institute, Imperial College London in the group of Prof Tim Williams, FRS  with Prof Jane Mitchell  whom he followed over from the WHRI. After completing his PhD, he then went to train with Prof Tim Hla at the University of Connecticut Health Center, where they initiated a research programme on nuclear receptors, before returning to the WHRI in Prof Tim Warner's group after obtaining a British Heart Foundation Intermediate Fellowship. In 2002 Dr Bishop-Bailey was then awarded a a British Heart Foundation Basic Science Lectureship and in 2004 was appointed as Senior Lecturer. After 13 years at the WHRI, Dr Bishop-Bailey then moved at the start of 2013 to the Department of Comparative Biomedical Sciences at the Royal Veterinary College, University of London. Dr Bishop-Bailey is currently a Fellow of the American Heart Association, the British Pharmacological Society, the Higher Education Authority and The Royal Society of Biology.

Dr Bishop-Bailey has a broad interest in the pharmacological, molecular and cellular aspects of lipid and eicosanoid biology, nuclear receptor signalling. and vascular and inflammation biology. Although focussed on vascular and inflammation research, the nature of the research opens it up to collaborative projects in many bioscience disciplines. Our research therefore has covered many areas including atherosclerosis, thrombosis, diabetes, metabolism, toxicology, breast cancer, airway disease, arthritis, ischemia-reperfusion injury, shock, Crohn's disease, ulcerative colitis, bacterial resistance, wound healing, and tissue regeneration. 

Epoxygenase inactivation exacerbates diet and aging-associated metabolic dysfunction resulting from impaired adipogenesis. Olona A, Terra X, Ko JH, Grau-Bové C, Pinent M, Ardevol A, Diaz AG, Moreno-Moral A, Edin M, Bishop-Bailey D, Zeldin DC, Aitman TJ, Petretto E, Blay M, Behmoaras J.Mol Metab. 2018 May;11:18-32.

Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2.
Proietti G, Abelak KK, Bishop-Bailey D, Macchiarulo A, Nobeli I. J Mol Model. 2016 Nov;22(11):279.

Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.
Moraes LA, Unsworth AJ, Vaiyapuri S, Ali MS, Sasikumar P, Sage T, Flora GD, Bye AP, Kriek N, Dorchies E, Molendi-Coste O, Dombrowicz D, Staels B, Bishop-Bailey D, Gibbins JM. ?Arterioscler Thromb Vasc Biol. 2016 Oct 6. pii: ATVBAHA.116.308093.

CYP450-derived oxylipins mediate inflammatory resolution.
Gilroy DW, Edin ML, De Maeyer RP, Bystrom J, Newson J, Lih FB, Stables M, Zeldin DC, Bishop-Bailey D. Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3240-9. doi: 10.1073/pnas.1521453113.

Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation.
Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL, Longhurst H, Zeldin DC, Mitchell JA, Warner TD.FASEB J. 2015 Jul 16. pii: fj.15-275065

Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Thomson S, Edin ML, Lih FB, Davies M, Yaqoob MM, Hammock BD, Gilroy D, Zeldin DC, Bishop-Bailey D.
Biochem Biophys Res Commun. 2015 Jun 15. pii: S0006-291X(15)30074-7. doi: 10.1016/j.bbrc.2015.06.012.

Nuclear receptors in vascular biology.
Bishop-Bailey D.
Curr Atheroscler Rep. 2015 May;17(5):507. doi: 10.1007/s11883-015-0507-8.

A thin layer angiogenesis assay: a modified basement matrix assay for assessment of endothelial cell differentiation.
Faulkner A, Purcell R, Hibbert A, Latham S, Thomson S, Hall WL, Wheeler-Jones C, Bishop-Bailey D.
BMC Cell Biol. 2014 Dec 5;15(1):41.

Lipid-Metabolizing CYPs in the Regulation and Dysregulation of Metabolism.
Bishop-Bailey D, Thomson S, Askari A, Faulkner A, Wheeler-Jones C.
Annu Rev Nutr. 2014;34:261-79.

Basal and inducible anti-inflammatory epoxygenase activity in endothelial cells.
Askari AA, Thomson S, Edin ML, Lih FB, Zeldin DC, Bishop-Bailey D.
Biochem Biophys Res Commun. 2014 Apr 4;446(2):633-7.

Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?
Bystrom J, Thomson SJ, Johansson J, Edin ML, Zeldin DC, Gilroy DW, Smith AM, Bishop-Bailey D.
PLoS One. 2013 Sep 13;8(9):e75107. doi: 10.1371/journal.pone.0075107.

Mechanisms governing the health and performance benefits of exercise.
Bishop-Bailey D.
Br J Pharmacol. 2013 Sep 6. doi: 10.1111/bph.12399. [Epub ahead of print]

Roles of the epoxygenase CYP2J2 in the endothelium.
Askari A, Thomson SJ, Edin ML, Zeldin DC, Bishop-Bailey D.
Prostaglandins Other Lipid Mediat. 2013 Dec;107:56-63. doi: 10.1016/j.prostaglandins.2013.02.003. Epub 2013 Mar 6.

The potential use of the pregnane X receptor in cardiovascular therapy.
Swales KE, Bishop-Bailey D.
Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1079-82. doi: 10.1586/erc.12.103. No abstract available.

Anti-inflammatory effects of epoxyeicosatrienoic acids.
Thomson SJ, Askari A, Bishop-Bailey D.
Int J Vasc Med. 2012;2012:605101. doi: 10.1155/2012/605101. Epub 2012 Jul 16.

Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress.
Swales KE, Moore R, Truss NJ, Tucker A, Warner TD, Negishi M, Bishop-Bailey D.
Cardiovasc Res. 2012 Mar 15;93(4):674-81. doi: 10.1093/cvr/cvr330. Epub 2011 Dec 13.

Dissecting the role of eosinophil cationic protein in upper airway disease.
Bystrom J, Patel SY, Amin K, Bishop-Bailey D.
Curr Opin Allergy Clin Immunol. 2012 Feb;12(1):18-23. doi: 10.1097/ACI.0b013e32834eccaf. Review.

PPARs and angiogenesis.
Bishop-Bailey D.
Biochem Soc Trans. 2011 Dec;39(6):1601-5. doi: 10.1042/BST20110643. Review.

Endogenous epoxygenases are modulators of monocyte/macrophage activity.
Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, Edin ML, Zeldin DC, Gilroy DW, Bishop-Bailey D.
PLoS One. 2011;6(10):e26591. doi: 10.1371/journal.pone.0026591. Epub 2011 Oct 19.

PPARα-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status.
Caton PW, Holness MJ, Bishop-Bailey D, Sugden MC.
Biochem J. 2011 Aug 1;437(3):521-30. doi: 10.1042/BJ20110702.

Analysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte.
Bystrom J, Amin K, Bishop-Bailey D.
Respir Res. 2011 Jan 14;12:10. doi: 10.1186/1465-9921-12-10. Review.

Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock.
Kapoor A, Shintani Y, Collino M, Osuchowski MF, Busch D, Patel NS, Sepodes B, Castiglia S, Fantozzi R, Bishop-Bailey D, Mota-Filipe H, Yaqoob MM, Suzuki K, Bahrami S, Desvergne B, Mitchell JA, Thiemermann C.
Am J Respir Crit Care Med. 2010 Dec 15;182(12):1506-15. doi: 10.1164/rccm.201002-0240OC. Epub 2010 Aug 6.

PPAR receptor activation: Experimental studies on cardiac structure and function.
Bishop-Bailey D.
Curr Opin Investig Drugs. 2010 Mar;11(3):283-8. Review.

The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo.
Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, Miller-Degraff L, Bradbury JA, Holness MJ, Warner TD, Bishop-Bailey D.
PLoS One. 2009 Oct 12;4(10):e7421. doi: 10.1371/journal.pone.0007421.

The platelet as a model system for the acute actions of nuclear receptors.
Bishop-Bailey D.
Steroids. 2010 Aug-Sep;75(8-9):570-5. doi: 10.1016/j.steroids.2009.09.005. Epub 2009 Sep 22. Review.

Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation.
Bishop-Bailey D, Bystrom J.
Pharmacol Ther. 2009 Nov;124(2):141-50. doi: 10.1016/j.pharmthera.2009.06.011. Epub 2009 Jul 15. Review.

Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release.
Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, Bishop-Bailey D.
J Leukoc Biol. 2009 Jul;86(1):115-22. doi: 10.1189/jlb.0508284. Epub 2009 Apr 23.

.
The Role of PPARs in the Endothelium: Implications for Cancer Therapy.
Bishop-Bailey D, Swales KE.
PPAR Res. 2008;2008:904251. doi: 10.1155/2008/904251. Epub 2008 Nov 24.

Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2.
Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, Bishop-Bailey D, Paul-Clark MJ, Tucker AT, Mitchell JA, Warner TD.
J Thromb Haemost. 2008 Nov;6(11):1933-43. doi: 10.1111/j.1538-7836.2008.03133.x. Epub 2008 Jan 11.

The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M.
J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401. doi: 10.1210/jc.2007-2611. Epub 2008 Apr 1.

Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D.
Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-11.

Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology.
Wray J, Bishop-Bailey D.
Exp Physiol. 2008 Jan;93(1):148-54. Epub 2007 Sep 14. Review.

Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets.
Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, Bishop-Bailey D.
Blood. 2007 May 1;109(9):3741-4. Epub 2007 Jan 9.

Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis.
Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D.
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):63-9. Epub 2006 Oct 26.

The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D.
Cancer Res. 2006 Oct 15;66(20):10120-6.

COX-2 in cardiovascular disease.
Bishop-Bailey D, Mitchell JA, Warner TD.
Arterioscler Thromb Vasc Biol. 2006 May;26(5):956-8. No abstract available.

Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Warner TD, Vojnovic I, Bishop-Bailey D, Mitchell JA.
FASEB J. 2006 Mar;20(3):542-4. Epub 2006 Jan 10.

Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta.
Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA.
FASEB J. 2006 Feb;20(2):326-8. Epub 2005 Dec 20.

Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.
Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA.
Am J Respir Cell Mol Biol. 2006 Feb;34(2):242-6. Epub 2005 Oct 20.

Peroxisome proliferator-activated receptors and inflammation.
Moraes LA, Piqueras L, Bishop-Bailey D.
Pharmacol Ther. 2006 Jun;110(3):371-85. Epub 2005 Sep 15. Review.

Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues.
Warner TD, Vojnovic I, Giuliano F, Jiménez R, Bishop-Bailey D, Mitchell JA.
J Pharmacol Exp Ther. 2004 Aug;310(2):642-7. Epub 2004 May 17.

Expression and activation of the farnesoid X receptor in the vasculature.
Bishop-Bailey D, Walsh DT, Warner TD.
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3668-73. Epub 2004 Feb 27.

PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist.
Bishop-Bailey D, Warner TD.
FASEB J. 2003 Oct;17(13):1925-7. Epub 2003 Aug 1.

Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.
Bishop-Bailey D, Wray J.
Prostaglandins Other Lipid Mediat. 2003 Apr;71(1-2):1-22. Review.

Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy.
Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA.
J Immunol. 2003 Mar 1;170(5):2663-9.

Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy.
Bishop-Bailey D, Hla T, Warner TD.
Circ Res. 2002 Aug 9;91(3):210-7.

Prostaglandins and the regulation of tumor growth.
Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA.
J Environ Pathol Toxicol Oncol. 2002;21(2):93-101. Review.

Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer.
Inoue K, Kawahito Y, Tsubouchi Y, Yamada R, Kohno M, Hosokawa Y, Katoh D, Bishop-Bailey D, Hla T, Sano H.
Anticancer Res. 2001 Jul-Aug;21(4A):2471-6.

Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line.
Bishop-Bailey D, Hla T, Warner TD.
Br J Pharmacol. 2000 Oct;131(4):651-4.

15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats.
Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H.
J Clin Invest. 2000 Jul;106(2):189-97.

Peroxisome proliferator-activated receptors in the cardiovascular system.
Bishop-Bailey D.
Br J Pharmacol. 2000 Mar;129(5):823-34. Review.

The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses.
Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ.
J Immunol. 2000 Feb 1;164(3):1364-71.

Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2.
Bishop-Bailey D, Hla T.
J Biol Chem. 1999 Jun 11;274(24):17042-8.

Cyclo-oxygenase-2 in vascular smooth muscle.
Bishop-Bailey D, Hla T, Mitchell JA.
Int J Mol Med. 1999 Jan;3(1):41-8. Review.

Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids.
Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA.
Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1655-61.

Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells.
Bishop-Bailey D, Burke-Gaffney A, Hellewell PG, Pepper JR, Mitchell JA.
Biochem Biophys Res Commun. 1998 Aug 10;249(1):44-7.

Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells.
Woods M, Bishop-Bailey D, Pepper JR, Evans TW, Mitchell JA, Warner TD.
J Cardiovasc Pharmacol. 1998;31 Suppl 1:S348-50.

Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery.
Bishop-Bailey D, Pepper JR, Haddad EB, Newton R, Larkin SW, Mitchell JA.
Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1644-8.

Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture.
Bishop-Bailey D, Larkin SW, Warner TD, Chen G, Mitchell JA.
Br J Pharmacol. 1997 May;121(1):125-33.

Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.
Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA.
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2046-50.

David teaches renal biology and inflammatory mediators on the BVetMed years 1 and 2 and GAB courses. He teaches vascular and inflammatory pharmacology on the year 2 BSc BioVeterinary Sciences Pharmacology and Applied Pharmacology modules. David is also the module lead for the research project and research skills modules for the year 4 MSci Biological and Bioveterianry Sciences course. David is an academic tutor to students in  years 1 and 2 of the BVetMed course, and supervises laboratory projects for students in year 3 of the BSc BioVeterinary Science course.

David has worked with Societies, such as the BPS, talking about commonly used painkillers at the Big Bang Fair, 2015, and the Royal Society of Biology on answering questions on gene-doping at New Scientist live, 2016. Updates on Dr Bishop-Baileys work can alos be found at www.bishopbailey.org

Top of page